Please wait while we load the requested 10-Q report or click the link below:
AGTC Announces Financial Results and Business Update for the Quarter Ended March 31, 2019
GAINESVILLE, Fla., and CAMBRIDGE, Mass., May 7, 2019 Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare diseases, today announced financial results for the quarter ended March 31, 2019.
Completing enrollment in the dose escalation portion of our Phase 1/2 trial in patients with achromatopsia due to mutations in the CNGB3 gene and the expansion cohort of our Phase 1/2 trial in patients with X-linked retinitis pigmentosa demonstrates our clinical development progress and keeps us on track to report multiple data sets in the second half of 2019, said Sue Washer, President and CEO of AGTC. Achieving these clinical milestones reflects our continued progress and commitment to developing new approaches to treat inherited retinal diseases positioning AGTC well to create value for patients and shareholders.
AGTC Clinical Program Update
AGTC remains on track to meet its current enrollment milestones across its three Phase 1/2 clinical programs:
X-linked Retinitis Pigmentosa (XLRP) Phase 1/2 Clinical Trial
To date, AGTC has completed enrollment of ten patients in the dose escalation portion of the XLRP trial and six patients in the expansion portion of the trial. The Company expects to:
Provide interim six-month data for the dose escalation group in the third quarter of 2019; and
Provide interim six-month data for the expansion group in the fourth quarter of 2019.
Achromatopsia (ACHM) Phase 1/2 Clinical Trials
The Company is enrolling patients in two parallel Phase 1/2 clinical trials of its product candidates for ACHM caused by mutations in the two most common ACHM genes, CNGB3 and CNGA3. To date, AGTC has enrolled twelve patients in the ACHM CNGB3 trial and seven patients in the ACHM CNGA3 trial. The Company expects to:
Complete enrollment of the dose escalation portion of the CNGA3 trial in the second quarter of 2019;
The following information was filed by Applied Genetic Technologies Corp (AGTC) on Tuesday, May 7, 2019 as an 8K 2.02 statement, which is an earnings press release pertaining to results of operations and financial condition. It may be helpful to assess the quality of management by comparing the information in the press release to the information in the accompanying 10-Q Quarterly Report statement of earnings and operation as management may choose to highlight particular information in the press release.
View differences made from one quarter to another to evaluate Applied Genetic Technologies Corp's financial trajectory
Compare this 10-Q Quarterly Report to its predecessor by reading our highlights to see what text and tables were
removed , and by Applied Genetic Technologies Corp.